Do I need a prescription for Co-dergocrine mesilate 1.5mg tablets?

Co-dergocrine mesilate 1.5mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Co-dergocrine mesilate 1.5mg tablets?

Co-dergocrine mesilate 1.5mg tablets is the generic name. It is available under brand names including: Hydergine 1.5mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Co-dergocrine mesilate 1.5mg tablets

Tablet

1.5mg

Oral

Active ingredients:

Co-dergocrine mesilate

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

C04AE01

WHO Anatomical Therapeutic Chemical code

Check interactions for Co-dergocrine mesilate

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Browse all Drug Analysis Profiles A–Z

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

Search EudraVigilance database

Browse substances A–Z in the European adverse reaction database

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Co-dergocrine mesilate on the MHRA register

Hydergine 1.5mg tablets

Novartis Pharmaceuticals UK Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Daily dose

WHO defined daily dose (DDD)

3 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

1 similar

Co-dergocrine mesilate 4.5mg tablets

Tablet

4.5mg

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

36090311000001101

dm+d ID

36090311000001101

VTM (Virtual Therapeutic Moiety)

34158411000001101

VMP (Virtual Medicinal Product)

36090311000001101

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C04AE01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 9 · Randomised trials: 3 · 1982–2025

Sort

Safety study of Nafamostat mesilate for continuous renal replacement therapy in intensive care patients：a systematic review and metaanalysis

song bin, liu chun

2024

Systematic review

Efficacy and safety of Nafamostat Mesilate for sepsis (EASNMS) : study protocol for a multicenter randomized controlled trial

Hongyu Yang, Jianshuang Feng, Yuteng Ma, et al.

2025

Randomised trial

Open access

Abstract Background Sepsis is the leading cause of death in critically ill patients, with an in-hospital mortality rate of approximately 25–40%. Coagulation activation serves as an initial factor to the progression of sepsis into multiple organ dysfunction syndrome (MODS). Therefore, anticoagulant therapy may be beneficial. Both basic experiments and clinical studies have evaluated the protective effect of Nafamostat Mesilate (NM) in sepsis. However, there is still a lack of randomized controlled trials (RCTs) to further confirm the therapeutic effect and safety of NM in sepsis patients. Methods This multicenter, double-blind, RCT was designed to recruit 778 subjects who met Sepsis 3.0 criteria. Participants will be randomly assigned (1:1) to receive either intravenous administration of NM or glucose along with standard treatment. The primary outcome is the all-cause mortality rate in the intensive care unit (ICU), and the secondary outcomes include the improvement in SOFA scores, changes in Japanese Association for Acute Medicine (JAAM)/International Society on Thrombosis and Hemostasis (ISTH) scores, 28-day all-cause mortality rate, and the incidence of adverse events. The allocation will remain concealed from investigators, participants, and statisticians to maintain blinding. Discussion The EASNMS trial aims to assess the efficacy and safety of NM for treating sepsis across various regions in China. As an additional treatment option, NM may potentially enhance the prognosis of sepsis patients. Trial registration ClinicalTrials.gov NCT06078839. Registered on September 20, 2023

Abstract licence: CC BY 4.0

Su1685 Nonsteroidal Anti-Inflammatory Drugs (Indomethacin and/or Diclofenac) and Protease Inhibitors (Gabexate Mesilate, Ulinastatin, and Nafamostat Mesilate) As a Prophylaxis Against Post-ERCP Pancreatitis, Updated Meta-Analysis

Mohamed M. Abdelfatah, Markus Agito, ALA Nijim, et al.

Gastrointestinal Endoscopy, 2014

Meta-analysis

Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate

A. Gomaa, M. Shalaby, M. Osman, et al.

BMJ, 1996

Randomised trial

Cited by 38

Penis
Impotence, Vasculogenic
Isosorbide Dinitrate

705 Prophylasix of Post-ERCP Pancreatitis With Nafamostat Mesilate: Comparison of 24-Hour and 8-Hour Infusion of Nafamostat Mesilate: a Prospective Randomized Comparison Trial

Wan Chul Kim, Joon Ho Jeon, Jae Gyu Shin, et al.

Gastrointestinal Endoscopy, 2015

Randomised trial

Camostat mesilate therapy for COVID-19

Yoshiharu Uno

Internal and Emergency Medicine, 2020

Cited by 83

Review for "Utility and safety of nafamostat mesilate for anticoagulation in dogs"

2022

Review

Decision letter for "Utility and safety of nafamostat mesilate for anticoagulation in dogs"

2022

Review

Author response for "Utility and safety of nafamostat mesilate for anticoagulation in dogs"

Noriko Isayama, Goki Matsumura, Yusuke Uchimura, et al.

2022

Review

Peer Review #2 of "Camostat mesilate inhibits pro-inflammatory cytokine secretion and improves cell viability by regulating MFGE8 and HMGN1 in lipopolysaccharide-stimulated DF-1 chicken embryo fibroblasts (v0.1)"

2021

Review

Open access

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

23 found

Half-life

3.5 hours

Mechanism

The general mechanism of action of ergoloid mesylate is the dual action of parti…

Food interactions

1 warning

Human targets

4 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

25%

The maximal plasma concentration of the components of the mixture of ergoloid mesylates is approximately 0.04…

Half-life

3.5 hours

The reported plasma half-life of ergoloid mesylate is 3.5 hours while the terminal half-life is of 13 hours.[T53]…

Protein binding

81%

Ergoloid mesylate presents a very large plasma protein binding that accounts for 81% of the administered dose.[F42]…

Volume of distribution

2 L/kg

The volume of distribution is about 2 L/kg.[T90] To know more about the individual components of the ergoloid mixture, please visit DB11274 and DB13345.…

Metabolism

Most of the metabolism of ergoloid mesylate is hepatic and it is performed very rapidly after absorption.…

Elimination

8.4%

The ergoloid mesylate mixture is mainly excreted via bile in feces.…

Clearance

To know more about the individual components of the ergoloid mixture, please visit DB11274 and DB13345.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.[A32912] All these components are produced by the fungus Claviceps purpurea and are all derivatives of the tetracyclic compound 6-methylergonovine.[T90] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives.[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued.[L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA.[L2640] To know more about the individual components of the ergoloid mixture, please visit DB11275, DB11274, DB11273 and DB13345.

Properties:

solid

DrugBank indication

It was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition[A32913] as well as for age-related cognitive impairment.
[A32926]
The prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary mood disturbance.
[L2637]
To know more about the individual components of the ergoloid mixture, please visit DB13345 and DB11274

Also known as(159)

co-dergocrine mesilate

co-dergocrine mesylate

co-dergocrine methanesulfonate

codergocrine mesilate

codergocrine mesylate

codergocrine methanesulfonate

Dihydroergotoxine Mesilate

Dihydroergotoxine Mesylate

Drug interactions(1231)

Known interactions with other medicines. Always consult a healthcare professional.

Valsartan

Moderate

DB00177

Ergoloid mesylate may decrease the antihypertensive activities of Valsartan.

Check this interaction

Ramipril

Moderate

DB00178

Ergoloid mesylate may decrease the antihypertensive activities of Ramipril.

Check this interaction

Remikiren

Moderate

DB00212

Ergoloid mesylate may decrease the antihypertensive activities of Remikiren.

Check this interaction

Torasemide

Moderate

DB00214

Ergoloid mesylate may decrease the antihypertensive activities of Torasemide.

Check this interaction

Guanadrel

Moderate

DB00226

Ergoloid mesylate may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Ergoloid mesylate may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Chlorthalidone

Moderate

DB00310

Ergoloid mesylate may decrease the antihypertensive activities of Chlorthalidone.

Check this interaction

Nitroprusside

Moderate

DB00325

Ergoloid mesylate may decrease the antihypertensive activities of Nitroprusside.

Check this interaction

Minoxidil

Moderate

DB00350

Ergoloid mesylate may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Treprostinil

Moderate

DB00374

Ergoloid mesylate may decrease the antihypertensive activities of Treprostinil.

Check this interaction

Bendroflumethiazide

Moderate

DB00436

Ergoloid mesylate may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Prazosin

Moderate

DB00457

Ergoloid mesylate may decrease the antihypertensive activities of Prazosin.

Check this interaction

Fosinopril

Moderate

DB00492

Ergoloid mesylate may decrease the antihypertensive activities of Fosinopril.

Check this interaction

Trandolapril

Moderate

DB00519

Ergoloid mesylate may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Metolazone

Moderate

DB00524

Ergoloid mesylate may decrease the antihypertensive activities of Metolazone.

Check this interaction

Benazepril

Moderate

DB00542

Ergoloid mesylate may decrease the antihypertensive activities of Benazepril.

Check this interaction

Cyclothiazide

Moderate

DB00606

Ergoloid mesylate may decrease the antihypertensive activities of Cyclothiazide.

Check this interaction

Candoxatril

Moderate

DB00616

Ergoloid mesylate may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Mecamylamine

Moderate

DB00657

Ergoloid mesylate may decrease the antihypertensive activities of Mecamylamine.

Check this interaction

Moexipril

Moderate

DB00691

Ergoloid mesylate may decrease the antihypertensive activities of Moexipril.

Check this interaction

Lisinopril

Moderate

DB00722

Ergoloid mesylate may decrease the antihypertensive activities of Lisinopril.

Check this interaction

Hydroflumethiazide

Moderate

DB00774

Ergoloid mesylate may decrease the antihypertensive activities of Hydroflumethiazide.

Check this interaction

Cryptenamine

Moderate

DB00785

Ergoloid mesylate may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Perindopril

Moderate

DB00790

Ergoloid mesylate may decrease the antihypertensive activities of Perindopril.

Check this interaction

Candesartan cilexetil

Moderate

DB00796

Ergoloid mesylate may decrease the antihypertensive activities of Candesartan cilexetil.

Check this interaction

Eprosartan

Moderate

DB00876

Ergoloid mesylate may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Chlorothiazide

Moderate

DB00880

Ergoloid mesylate may decrease the antihypertensive activities of Chlorothiazide.

Check this interaction

Quinapril

Moderate

DB00881

Ergoloid mesylate may decrease the antihypertensive activities of Quinapril.

Check this interaction

Telmisartan

Moderate

DB00966

Ergoloid mesylate may decrease the antihypertensive activities of Telmisartan.

Check this interaction

Hydrochlorothiazide

Moderate

DB00999

Ergoloid mesylate may decrease the antihypertensive activities of Hydrochlorothiazide.

Check this interaction

Trichlormethiazide

Moderate

DB01021

Ergoloid mesylate may decrease the antihypertensive activities of Trichlormethiazide.

Check this interaction

Deserpidine

Moderate

DB01089

Ergoloid mesylate may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Pentolinium

Moderate

DB01090

Ergoloid mesylate may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Ergoloid mesylate may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Diazoxide

Moderate

DB01119

Ergoloid mesylate may decrease the antihypertensive activities of Diazoxide.

Check this interaction

Bretylium

Moderate

DB01158

Ergoloid mesylate may decrease the antihypertensive activities of Bretylium.

Check this interaction

Terazosin

Moderate

DB01162

Ergoloid mesylate may decrease the antihypertensive activities of Terazosin.

Check this interaction

Captopril

Moderate

DB01197

Ergoloid mesylate may decrease the antihypertensive activities of Captopril.

Check this interaction

Epoprostenol

Moderate

DB01240

Ergoloid mesylate may decrease the antihypertensive activities of Epoprostenol.

Check this interaction

Polythiazide

Moderate

DB01324

Ergoloid mesylate may decrease the antihypertensive activities of Polythiazide.

Check this interaction

Cilazapril

Moderate

DB01340

Ergoloid mesylate may decrease the antihypertensive activities of Cilazapril.

Check this interaction

Saprisartan

Moderate

DB01347

Ergoloid mesylate may decrease the antihypertensive activities of Saprisartan.

Check this interaction

Spirapril

Moderate

DB01348

Ergoloid mesylate may decrease the antihypertensive activities of Spirapril.

Check this interaction

Tienilic acid

Moderate

DB04831

Ergoloid mesylate may decrease the antihypertensive activities of Tienilic acid.

Check this interaction

Debrisoquine

Moderate

DB04840

Ergoloid mesylate may decrease the antihypertensive activities of Debrisoquine.

Check this interaction

Diethylnorspermine

Moderate

DB06445

Ergoloid mesylate may decrease the antihypertensive activities of Diethylnorspermine.

Check this interaction

Temocapril

Moderate

DB08836

Ergoloid mesylate may decrease the antihypertensive activities of Temocapril.

Check this interaction

Trimazosin

Moderate

DB09206

Ergoloid mesylate may decrease the antihypertensive activities of Trimazosin.

Check this interaction

Nicorandil

Moderate

DB09220

Ergoloid mesylate may decrease the antihypertensive activities of Nicorandil.

Check this interaction

Rauwolfia serpentina root

Moderate

DB09363

Ergoloid mesylate may decrease the antihypertensive activities of Rauwolfia serpentina root.

Check this interaction

Showing 50 of 1231 interactions

Food & lifestyle interactions

Advice

Take with or without food. Taking ergoloid mesylate with food may reduce gastrointestinal upset.

Toxicity & overdose

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia. The excessive use of ergoloid mesylate can lead to ergotism.[T90] To know more about the individual components of the ergoloid mixture, please visit DB11274, DB11273 and DB13345.

How it works

Mechanism of action

The general mechanism of action of ergoloid mesylate is the dual action of partial agonism/antagonism of adrenergic, dopaminergic and serotonergic receptors. The pharmacological activity is determined by the degree of activity of each component at the receptor site.[T90] To know more about the individual components of the ergoloid mixture, please visit DB11275, DB11274, DB11273 and DB13345.

Pharmacodynamics

The mechanism of action of ergoloid mesylate is not completely established but it is thought that it increases both the blood flow and cerebral metabolism. Some studies have shown a significant improvement in alertness and memory, as well as a decline in confusion while some other benefits have shown a lack of effect.[A32913] Its action produces a damper in the impulses from the vasomotor center which reduces the vascular tone which translates in the slow of pulse rate, prevention of compensatory tachycardia.[A32914] To know more about the individual components of the ergoloid mixture, please visit DB11274, DB11273 and DB13345.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

The maximal plasma concentration of the components of the mixture of ergoloid mesylates is approximately 0.04 mcg/l. The analysis of the concentration of the major metabolites of each component indicates that all ergoloid mesylate are rapidly transformed after absorption. This finding is supported as they were found in one order of magnitude higher in concentration when compared to the original form.
[A32914]
Ergoloid mesylate seems to have a very low absorption of only 25%.

From this absorption by the GI tract, approximately 50% of the absorbed dose is eliminated by first-pass metabolism. After absorption, the maximal plasma concentration is attained after 3-4 hours and the oral bioavailability is very low.[T53] Simultaneous food ingestion has no effect on the extent of absorption but it does lower the absorption rate.
[A32937]
To know more about the individual components of the ergoloid mixture, please visit DB11274, DB11273 and DB13345.

Half-life

The reported plasma half-life of ergoloid mesylate is 3.5 hours while the terminal half-life is of 13 hours.[T53] To know more about the individual components of the ergoloid mixture, please visit DB11274.

Protein binding

Ergoloid mesylate presents a very large plasma protein binding that accounts for 81% of the administered dose.[F42] To know more about the individual components of the ergoloid mixture, please visit DB11274 and DB13345.

Volume of distribution

The volume of distribution is about 2 L/kg.[T90] To know more about the individual components of the ergoloid mixture, please visit DB11274 and DB13345.

Metabolism

Most of the metabolism of ergoloid mesylate is hepatic and it is performed very rapidly after absorption. After exposition in vitro, the major metabolites identified are hydroxy-dihydroergocornine, hydroxy-dihydroergocryptine and hydroxy-dihydroergocristine.
[A32926]
All metabolic transformations seem to be related to the activity of the cytochrome CYP3A4.
[L2681]
To know more about the individual components of the ergoloid mixture, please visit DB11274, DB11273 and DB13345.

Route of elimination

The ergoloid mesylate mixture is mainly excreted via bile in feces. The ratio of the eliminated dose via urine after intravenous and oral administration is 8.4% and 2% respectively.[T53] Urinary excretion of the unchanged drug is very small and bile excretion is represented mainly by ergot metabolites conformed as conjugated compounds.[T191] To know more about the individual components of the ergoloid mixture, please visit DB11274, DB11273 and DB13345.

Clearance

To know more about the individual components of the ergoloid mixture, please visit DB11274 and DB13345.

Drug targets(4)

Proteins and enzymes this drug interacts with in the body

D(4) dopamine receptor

BE0009376

DRD4

antagonist

agonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Activated by dopamine, but also by epinephrine and norepinephrine, and by numerous synthetic agonists and drugs .
PMID:16423344 PMID:27659709 PMID:29051383 PMID:9003072

Agonist binding triggers signaling via G proteins that inhibit adenylyl cyclase .
PMID:16423344 PMID:27659709 PMID:29051383 PMID:7512953 PMID:7643093

Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity)

Alpha-2C adrenergic receptor

BE0004888

ADRA2C

antagonist

agonist

Specific functionalpha-2A adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins

Beta-3 adrenergic receptor

BE0004872

ADRB3

antagonist

agonist

Specific functionbeta-3 adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis

5-hydroxytryptamine receptor 7

BE0004862

HTR7

antagonist

agonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen .
PMID:35714614 PMID:8226867
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:35714614 PMID:8226867
HTR7 is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity PMID:35714614

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

Scientific references(5)

Thompson TL 2nd, Filley C.M., Mitchell W.D., Culig K.M., LoVerde M., Byyny R.L.

Lack of efficacy of hydergine in patients with Alzheimer's disease.

New England Journal of Medicine

1990 Aug 16323(7):445-8. doi: 10.1056/NEJM199008163230704

PMID: 2082953 DOI: 10.1056/NEJM199008163230704

Delagarza V.W.

Challenges with new treatments for Alzheimer disease.

Canadian Family Physician

202369(3):160-161. doi: 10.46747/cfp.6903160

PMID: 9787282 DOI: 10.46747/cfp.6903160

PERCHESON P.B., CARROLL J.J.

Hydergine therapy of uterine inertia.

Canadian Anaesthetists’ Society Journal

19541(2):87-94. doi: 10.1007/bf03015824

PMID: 13209453 DOI: 10.1007/bf03015824

Bicalho B., Giolo J.M., Lilla S., De Nucci G.

Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results.

Biopharm Drug Disposition

2008 Jan29(1):17-28. doi: 10.1002/bdd.585

PMID: 17941060 DOI: 10.1002/bdd.585

Schran H.F., McDonald S., Lehr R.

Pharmacokinetics and bioavailability of ergoloid mesylates.

Biopharm Drug Disposition

1988 Jul-Aug9(4):349-61. doi: 10.1002/bod.2510090404

PMID: 3207855 DOI: 10.1002/bod.2510090404

Affected organisms(1)

Humans and other mammals

Experimental properties(4)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Ergoloid mesylate

Matched from: Co-dergocrine mesilate

DB01049

CAS number

8067-24-1

UNII (FDA)

X3S33EX3KW

Synonym match

95% confidence

Additional database identifiers

Drugs Product Database (DPD)

1411

ChEBI

34706

PubChem Substance

46505963

KEGG Compound

C14055

KEGG Drug

D02268

ChemSpider

60600935

PharmGKB

PA164752439

Therapeutic Targets Database

DAP000901

Wikipedia

Ergoloid

RxCUI

4024

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3025

GenAtlas

DRD4

GeneCards

DRD4

GenBank Gene Database

L12398

GenBank Protein Database

291946

IUPHAR

217

Guide to Pharmacology

217

UniProtKB

P21917

UniProt Accession

DRD4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:285

GenAtlas

ADRB1

GeneCards

ADRB1

GenBank Gene Database

J03019

GenBank Protein Database

178200

IUPHAR

Guide to Pharmacology

UniProtKB

P08588

UniProt Accession

ADRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:286

GenAtlas

ADRB2

GeneCards

ADRB2

GenBank Gene Database

Y00106

GenBank Protein Database

29371

IUPHAR

Guide to Pharmacology

UniProtKB

P07550

UniProt Accession

ADRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:288

GenAtlas

ADRB3

GeneCards

ADRB3

GenBank Gene Database

M29932

GenBank Protein Database

178896

IUPHAR

Guide to Pharmacology

UniProtKB

P13945

UniProt Accession

ADRB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5287

GenAtlas

HTR1B

GeneCards

HTR1B

GenBank Gene Database

D10995

GenBank Protein Database

219679

IUPHAR

Guide to Pharmacology

UniProtKB

P28222

UniProt Accession

5HT1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5289

GenAtlas

HTR1D

GeneCards

HTR1D

GenBank Gene Database

M89955

GenBank Protein Database

177772

IUPHAR

Guide to Pharmacology

UniProtKB

P28221

UniProt Accession

5HT1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5291

GenAtlas

HTR1E

GeneCards

HTR1E

GenBank Gene Database

M91467

GenBank Protein Database

177774

IUPHAR

Guide to Pharmacology

UniProtKB

P28566

UniProt Accession

5HT1E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5292

GenAtlas

HTR1F

GeneCards

HTR1F

GenBank Gene Database

L05597

GenBank Protein Database

307420

IUPHAR

Guide to Pharmacology

UniProtKB

P30939

UniProt Accession

5HT1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5294

GenAtlas

HTR2B

GeneCards

HTR2B

GenBank Gene Database

X77307

GenBank Protein Database

475198

IUPHAR

Guide to Pharmacology

UniProtKB

P41595

UniProt Accession

5HT2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5297

GenAtlas

HTR3A

GeneCards

HTR3A

GenBank Gene Database

D49394

GenBank Protein Database

681914

IUPHAR

373

Guide to Pharmacology

373

UniProtKB

P46098

UniProt Accession

5HT3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5298

GeneCards

HTR3B

Guide to Pharmacology

374

UniProtKB

O95264

UniProt Accession

5HT3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24003

GeneCards

HTR3C

UniProtKB

Q8WXA8

UniProt Accession

5HT3C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24004

GeneCards

HTR3D

UniProtKB

Q70Z44

UniProt Accession

5HT3D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24005

GeneCards

HTR3E

UniProtKB

A5X5Y0

UniProt Accession

5HT3E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5299

GenAtlas

HTR4

GeneCards

HTR4

GenBank Gene Database

Y12505

GenBank Protein Database

2661757

IUPHAR

Guide to Pharmacology

UniProtKB

Q13639

UniProt Accession

5HT4R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5301

GenAtlas

HTR6

GeneCards

HTR6

GenBank Gene Database

L41147

GenBank Protein Database

1162924

IUPHAR

Guide to Pharmacology

UniProtKB

P50406

UniProt Accession

5HT6R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 8 Mar 2026

Back to medicines

Co-dergocrine mesilate 1.5mg tablets

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
5

Chemical identifiers

Ergoloid mesylate

Additional database identifiers

DrugBank citations

Co-dergocrine mesilate 1.5mg tablets

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science5

Chemical identifiers

Ergoloid mesylate

Additional database identifiers

DrugBank citations

Deep science
5